Clinical trials: Substance Dependency
- Condition Substance Dependency
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Nicotine Dependence, Nicotine Dependence, Cigarettes
Clinical Study Comparing 7 ENDS Products and 1 Combustible Cigarette Using 2 Delivery Methods.
A Randomized Study Comparing Nicotine Pharmacokinetics of Seven Electronic Cigarette Products and One Traditional Cigarette Across Two Delivery (10 puff and ad- libitum) Conditions, in Healthy Adult Smokers
- Conditions
- Nicotine Dependence, Nicotine Dependence, Cigarettes, Tobacco Use, Tobacco Smoking
- Trial name
- NCT03700112
- Testing
- JUUL Virginia Tobacco flavored 5.0% ENDS, PMI iQOS Heat sticks, Reynolds VUSE Solo ENDS - Original
- Where
- New Zealand
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Juul Labs, Inc.
Nicotine Dependence, Nicotine Dependence, Cigarettes
United States Pre-Market Tobacco Application Pharmacokinetics
A Randomized, Open-Label, Cross-Over Study to Assess Nicotine Uptake and Subjective Measures with Use of JUUL 5% Electronic Nicotine Delivery Systems (ENDS) Compared to Usual Brand Combustible Cigarettes, a Comparator…
- Conditions
- Nicotine Dependence, Nicotine Dependence, Cigarettes, Tobacco Use, Tobacco Smoking
- Trial name
- US-PMTA-PK (NCT03719391)
- Testing
- Virginia Tobacco flavored JUUL 5% ENDS, Cool Mint flavored JUUL 5% ENDS, Mango flavored JUUL 5% ENDS
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Juul Labs, Inc.
Tobacco Use Disorder, Tobacco Dependence
Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke
This study will consist of 2 phases. Phase 1 will be a one day crossover study to see the effects of study product on a smoker's desire to smoke, measured by changes in scores on questionnaires given over time.
- Conditions
- Tobacco Use Disorder, Tobacco Dependence, Smoking
- Trial name
- NCT01428310
- Testing
- Anatabloc(TM), CigRx(R)
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Rock Creek Pharmaceuticals, Inc.
Substance Dependence
Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809
GSK598809 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders.
- Trial name
- NCT00437632
- Testing
- GSK598809, Caffeine
- Where
- United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Substance Dependence
A Healthy Volunteer Study to Investigate the Relative Bioavailability of Two Forms of GSK598809 Capsules.
Study to compare PK of a new 100mg capsule with four 25mg capsules. This is required because we plan to have only single capsules administered in the later phase clinical trials but we have not had a 100mg strength before.
- Trial name
- NCT00728897
- Testing
- GSK598809 new formulation, GSK598809 old formulation
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Opiate Dependence
Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers
The primary objective of this study is to compare the bioavailability of a test formulation of Buprenorphine Naloxone Sublingual (SL) spray to that of a single dose of Suboxone® (buprenorphine and naloxone) sublingual film, under…
- Trial name
- NCT02477267
- Testing
- SL spray, SL film
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- INSYS Therapeutics Inc
Tobacco Dependence
Clinical Study to Assess Bioequivalence Between Nicorette Extra Mint Gum and Nicorette® Mint Gum in Healthy Smokers
This is a research study to verify the same effectiveness and safety profile for the test products, nicotine 2 mg gum and nicotine 4 mg gum, as for the already approved products, Nicorette Mint 2 mg gum and Nicorette Mint 4 mg…
- Trial name
- NCT03259607
- Testing
- Nicorette Extra Mint 2 mg Gum, Nicorette Mint 2 mg Gum, Nicorette Extra Mint 4mg Gum
- Where
- China
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- McNeil AB
Substance Dependence
Effects of the D3 Antagonist GSK598809 on Food Reward and Reinforcement
This novel compound is a new experimental treatment that may help people to stop compulsive overeating. Compulsive overeating or binge eating is one of the main reasons why people are overweight or obese.
- Trial name
- NCT01039454
- Testing
- GSK598809 Capsules
- Where
- 2 sites in United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cigarette Smoking
Nicotine Pharmacokinetics From Research Electronic Nicotine Delivery System S-TA-U001 in Smokers and E-Cigarette Users
To better understand the PK and associated pharmacodynamic (PD) responses produced by the Research ENDS S-TA-U001 product, this study will compare the Research ENDS S-TA-U001 to The subject's own brand combustion (non-menthol)…
- Trial name
- NCT02792426
- Testing
- Research ENDS S-TA-U001, Nicorette Inhalator
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- NJOY, Inc.
Tobacco Dependence
CO Monitoring for Tobacco Cessation in Quitlines
The present study is a 3-arm randomized controlled pilot study. Participants who call the Maryland Tobacco Quitline and are eligible for study participation are randomized to receive quitline tobacco cessation treatment as usual…
- Trial name
- NCT05327660
- Testing
- Quitline Treatment as Usual (TAU), Remote Carbon Monoxide (CO) Monitoring, Incentivized Remote CO Monitoring
- Where
- United States
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- Consumer Wellness Solutions
Alcohol Dependence
A Study of Brain Receptor Occupancy in Healthy Subjects
To measure the occupancy of brain kappa opioid receptors after single oral doses of LY2456302.
- Trial name
- NCT01232439
- Testing
- opioid receptor kappa antagonist
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Opiate Dependence
ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids
This was a Phase 2, multicenter, randomized, double-blind pilot study in opioid-using adults to assess the presence, duration, and degree of opiate blockade as well as the safety and tolerability of Medisorb® naltrexone…
- Trial name
- NCT01218984
- Testing
- Medisorb naltrexone 75 mg, Medisorb naltrexone 150 mg, Medisorb naltrexone 300 mg
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Opioid Dependence, Opioid Related Disorders
A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse
This is a randomized, 4-sequence, 2-period, double-blind, placebo controlled study in male and female subjects with an American Psychiatric Association Diagnostic and Statistical Manual DSM-IV-TR diagnosis of cocaine abuse.
- Conditions
- Opioid Dependence, Opioid Related Disorders, Cocaine Dependence
- Trial name
- RBP-8000 (NCT01846481)
- Testing
- RBP-8000 100 mg, Cocaine, RBP-8000 200 mg
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.
Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders
Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories
This research is being done to evaluate if NRP 104 is a safe drug. The other purpose is to learn if NRP104, when injected into a vein, produces a high and any other effects like amphetamine and other stimulant drugs that are…
- Conditions
- Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
- Trial name
- NCT00247572
- Testing
- NRP104
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- New River Pharmaceuticals
Substance Dependence
EtOH Interaction Study
This study will investigate the possible effects of alcohol in combination with GSK598809 on the central nervous system in 20 healthy male and female volunteers, between 18 and 65 years of age.
- Trial name
- NCT00887367
- Testing
- GSK598809, Ethanol
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Thromboangiitis Obliterans (Buerger's Disease)
A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers
This study is a first-in-human clinical trial of drug ATI-1013, in healthy adult cigarette smokers. The main questions it aims to answer are to learn about the safety of drug ATI-1013, how long drug ATI-1013 remains within the…
- Trial name
- NCT07215923
- Testing
- ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Antidote Therapeutics, Inc
Smoking Cessation, Harm Reduction
Assisting Smokers to Switch to a JUUL E-Cigarette by Devaluing Combustible Cigarettes
This study will evaluate a reward devaluation strategy in which smokers use the JUUL e-cigarette immediately before any combustible cigarettes (CCs) are smoked.
- Conditions
- Smoking Cessation, Harm Reduction, E-Cig Use, Cigarette Smoking
- Trial name
- RECON (NCT04188197)
- Testing
- JUUL
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Substance Dependence
To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood Levels Of GSK618334
GSK618334 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders.
- Trial name
- NCT00513279
- Testing
- GSK618334
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alcohol Abuse, Alcohol Dependence
Remote Brief Intervention and Referrals to Treatment Service for Alcohol
The traditional paradigm that relies upon training physicians and nurses or uses on-site interventionists to perform screening, brief intervention, and referral to treatment (SBIRT) for alcohol has proven unsustainable in most…
- Trial name
- RBIRT (NCT02622984)
- Testing
- RBIRT, SBIRT
- Where
- United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Polaris Health Directions
Substance Dependence
An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy Male Subjects Using 11C-PHNO as PET Ligand
The purpose of this study is to investigate the relationship between the plasma concentrations of the study drug and the amount of the study drug bound to the D3 receptors of the brain after dosing of a new compound GSK618334.
- Trial name
- NCT00814957
- Testing
- GSK618334
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline